1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. Company
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Delayed London Stock Exchange  -  11:35 2022-08-16 am EDT
1425.00 GBX   +1.35%
04:29pPlaintiff in first Zantac lawsuit set for trial drops case
RE
03:57pSECTOR UPDATE : Health Care Stocks Edging Lower Near Tuesday Close
MT
03:38pSECTOR UPDATE : Health Care
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo GSK plc
GSK plc, formerly GlaxoSmithKline PLC is a global healthcare company. The Company is focused to improve the quality of human life by helping people. The Company operates through three core businesses: Pharmaceuticals, Vaccines and Consumer Healthcare. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency viruses (HIV), immuno-inflammation and oncology. It also focuses on immunology, human genetics, and advanced technologies to deliver transformational new medicines for patients. The Company's research and development focuses on developing vaccines against infectious diseases that combine high medical needs and market potential. The Company's Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands for oral health, pain relief, cold, flu and allergy, digestive health, and vitamins, minerals and supplements. It provides prescription medicines, vaccines, and consumer healthcare products.

Number of employees : 90 096 people.
Sales per Business
20202021Delta
Pharmaceuticals17 056.0050%17 729.0052% +3.95%
Consumer Healthcare10 033.0029.4%9 607.0028.2% -4.25%
Vaccines6 982.0020.5%6 778.0019.9% -2.92%
Corporate and Other Unallocated28.000.1%---
GBP in Million
Sales per region
20202021Delta
United States14 556.0042.7%15 093.0044.2% +3.69%
Rest of World11 379.0033.4%11 183.0032.8% -1.72%
Europe7 184.0021.1%6 863.0020.1% -4.47%
United Kingdom980.002.9%975.002.9% -0.51%
GBP in Million
Managers
Name Title Age Since
Emma Walmsley Chief Executive Officer & Executive Director 51 2017
Iain Mackay Chief Financial Officer & Executive Director 59 2019
Jon Ellis VP & Head-Technology Business Development 54 2019
Tony Wood Chief Scientific Officer - 2022
Amy Altshul SVP-Legal, Research & Development - -
Shobie Ramakrishnan Chief Digital & Technology Officer - 2021
James Ford Group General Counsel, Head-Legal & Compliance - 2018
Sarah-Jane Hall Group Treasurer & Senior Vice President - -
Victoria A. Whyte Secretary - 2009
Philip Thomson President-Global Affairs - 2017
Members of the board
Name Title Age Since
Jonathan Symonds Non-Executive Chairman 62 2019
Urs Rohner Independent Non-Executive Director 62 2015
Jesse L. Goodman, Dr. Independent Non-Executive Director 69 2016
Laurie H. Glimcher, Dr. Independent Non-Executive Director 69 2017
Charles Bancroft Senior Independent Non-Executive Director 61 2022
Anne C. Beal, Dr. Independent Non-Executive Director - 2021
Harry C. Dietz, Dr. Independent Non-Executive Director - 2022
Emma Walmsley Chief Executive Officer & Executive Director 51 2017
Hal Barron Non-Independent Non-Executive Director 58 2022
Iain Mackay Chief Financial Officer & Executive Director 59 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 4,311,277,892 4,035,728,201 93.6% 0 0.0% 93.6%
Shareholders
NameEquities%
The Vanguard Group, Inc. 130,463,200 3.21%
BlackRock Fund Advisors 110,062,400 2.71%
Dodge & Cox 94,377,360 2.32%
Norges Bank Investment Management 89,932,000 2.21%
Schroder Investment Management Ltd. 70,199,790 1.73%
BlackRock Advisors (UK) Ltd. 62,174,742 1.53%
Capital Research & Management Co. (Global Investors) 59,954,292 1.47%
Legal & General Investment Management Ltd. 56,682,594 1.39%
Silchester International Investors LLP 53,287,200 1.31%
SIX SIS Ltd. 49,699,200 1.22%
Holdings
NameEquities%Valuation
VIR BIOTECHNOLOGY, INC. (VIR) 8,550,954 6.46% 237,802,031 USD
LYELL IMMUNOPHARMA, INC. (LYEL) 30,253,189 12.3% 168,510,263 USD
GLAXOSMITHKLINE PAKISTAN LIMITED (GLAXO) 263,029,794 82.6% 130,523,275 USD
GLAXOSMITHKLINE S.A.E (BIOC) 76,161,378 91.2% 99,992,273 USD
GLAXOSMITHKLINE CONSUMER HEALTHCARE PAKISTAN LIMITED (GSKCH) 100,423,259 85.8% 91,565,928 USD
THERAVANCE BIOPHARMA, INC. (TBPH) 9,644,807 12.7% 84,777,854 USD
BICYCLE THERAPEUTICS LIMITED 1,529,561 5.17% 36,036,457 USD
DONG-A SOCIO HOLDINGS CO., LTD. (A000640) 409,693 6.45% 31,473,608 USD
FULCRUM THERAPEUTICS, INC. (FULC) 1,785,714 4.37% 10,499,998 USD
ALLERGY THERAPEUTICS PLC (AGY) 10,118,000 1.57% 2,339,383 USD
Company contact information
GSK Plc
980 Great West Road
Brentford
Middlesex, Greater London TW8 9GS

Phone : +44.20.8047.5000
Fax : +44.20.8047.7807
Web : http://gsk.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of GSK plc
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
GSK PLC-14.46%68 741
JOHNSON & JOHNSON-2.91%436 680
ELI LILLY AND COMPANY13.66%298 298
PFIZER, INC.-15.75%279 215
ROCHE HOLDING AG-16.14%277 502
ABBVIE INC.5.09%251 582
NOVO NORDISK A/S5.65%241 077
MERCK & CO., INC.18.22%229 515
ASTRAZENECA PLC26.32%205 131
NOVARTIS AG0.21%185 841
BRISTOL-MYERS SQUIBB COMPANY19.53%159 141
AMGEN INC.11.61%134 310
SANOFI-3.91%108 513
DAIICHI SANKYO CO., LTD.43.97%60 658
BAYER AG13.96%53 578
CHUGAI PHARMACEUTICAL CO., LTD3.56%47 815
TAKEDA PHARMACEUTICAL COMPANY LIMITED21.17%44 162
JIANGSU HENGRUI MEDICINE CO., LTD.-28.12%34 753
ASTELLAS PHARMA INC.9.60%28 146
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-32.20%26 554
CATALENT, INC.-13.42%19 866